Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

May 26, 2026 6:52 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $1,245.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments